Skip to main content
SpringerLink
Log in

Novel Antiplatelet Therapies

  • Nonstatin Drugs (W Borden, Section Editor)
  • Published:
Current Atherosclerosis Reports Aims and scope Submit manuscript

Abstract

Advances in antiplatelet therapy have significantly improved outcomes in patients with ischemic heart disease. Thienopyridines remain a cornerstone of therapy along with aspirin. Recently, concerns have been raised about the use of clopidogrel due to its pharmacokinetic and pharmacogenetic interpatient variability. A third-generation thienopyridine, prasugrel, overcomes some of these problems by improving inhibition of platelet aggregation, but increasing the risk of peri-procedural bleeding. Other novel antiplatelet agents, such as ticagrelor, have shown improved efficacy in recent trials and require further investigations. The field of pharmacotherapy continues to rapidly evolve as newer agents, such as thrombin receptor antagonists, along with older agents, such as cilostazol and glycoprotein IIb/IIIa inhibitors, are being explored.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Rosamond W, Flegal K, Friday G, et al. Heart disease and stroke statistics—2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2007;115:e69–e171.

    Article  PubMed  Google Scholar 

  2. Zipes DP, Libby P, Bonow RO, et al. Brauwalds heart disease: a textbook of cardiovascular medicine. 7th ed. Philadelphia: Saunders; 2005.

    Google Scholar 

  3. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation. 2007;116:e148–304.

    Article  PubMed  Google Scholar 

  4. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction – executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). Circulation. 2004;110:588–636.

    Article  PubMed  Google Scholar 

  5. EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein IIb/IIIa blockade. Lancet. 1998;52:87–92.

    Article  Google Scholar 

  6. ESPRIT Investigators. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomized, placebo-controlled trial. Lancet. 2000;356:2037–44.

    Article  Google Scholar 

  7. Lewis HD, Davis JW, Archibald DG, et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study. N Engl J Med. 1983;309:396–403.

    Article  PubMed  Google Scholar 

  8. Cairns JA, Gent M, Singer J, et al. Aspirin, sulfinpyrazone, or both in unstable angina. Results of a Canadian multicenter trial. N Engl J Med. 1985;313:1369–75.

    Article  PubMed  CAS  Google Scholar 

  9. Theroux P, Ouimet H, McCans J, et al. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med. 1988;319:1105–11.

    Article  PubMed  CAS  Google Scholar 

  10. The RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet. 1990;336:827–30.

    Article  Google Scholar 

  11. ISIS–2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS–2. Lancet. 1988;2:349–60.

    Google Scholar 

  12. Mehta SR, Tanguay JF, Eikelboom JW, et al. (CURRENT-OASIS 7 trial investigators) double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet. 2010;376:1233–43.

    Article  PubMed  CAS  Google Scholar 

  13. Steinhubl SR, Tan WA, Foody JM, et al. Incidence and clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stenting. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. JAMA. 1999;281:806–10.

    Article  PubMed  CAS  Google Scholar 

  14. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348:1329–39.

    Article  Google Scholar 

  15. Yusuf S, Zhao F, Mehta SR, et al. Clopidogrel in unstable angina to prevent recurrent events trial investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494–502.

    Article  PubMed  CAS  Google Scholar 

  16. Steinhubl SR, Berger PB, Mann 3rd JT, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;288:2411–20.

    Article  PubMed  CAS  Google Scholar 

  17. Sabatine MS, Cannon CP, Gibson CM, et al. For the CLARITY-TIMI 28 investigators. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med. 2005;352:1179–89.

    Article  PubMed  CAS  Google Scholar 

  18. Chen ZM, Jiang LX, Chen YP, et al. COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005;366:1607–21.

    Article  PubMed  CAS  Google Scholar 

  19. Patti G, Colonna G, Pasceri V, et al. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) Study. Circulation. 2005;111:2099–106.

    Article  PubMed  CAS  Google Scholar 

  20. Von Beckerath N, Taubert D, Pogatsa-Murray G, et al. Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel. Results of the ISAR-CHOICE (Intracoronary stenting and antithrombotic regimen: choose between 3 high oral doses for immediate clopidogrel effect) Trial. Circulation. 2005;112:2946–50.

    Google Scholar 

  21. Rupprecht HJ, Widimsky P, Afzal R, et al. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med. 2010;363:930–42.

    Article  PubMed  Google Scholar 

  22. Kazui M, Nishiya Y, Ishizuka T, et al. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metabol Dispos. 2010;38:92–9.

    Article  CAS  Google Scholar 

  23. Gilard M, Arnaud B, Le Gal G, Abgrall JF, Boschat J. Influence of omeprazol on the antiplatelet action of clopidogrel associated to aspirin. J Thromb Haemost. 2006;4:2508–9.

    Article  PubMed  CAS  Google Scholar 

  24. Gilard M, Arnaud B, Cornily JC, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol. 2008;51:256–60.

    Article  PubMed  CAS  Google Scholar 

  25. Cuisset T, Frere C, Quilici J, et al. Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose. The PACA (Proton Pump Inhibitors and clopidogrel Association) prospective randomized study. J Am Coll Cardiol. 2009;54:1149–53.

    Article  PubMed  CAS  Google Scholar 

  26. Sibbing D, Morath T, Stegherr J, et al. Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb Haemost. 2009;101:714–9.

    PubMed  CAS  Google Scholar 

  27. Neubauer H, Engelhardt A, Kruger JC, et al. Pantoprazole does not influence the antiplatelet effect of clopiodgrel: a whole blood aggregometry study after coronary stenting. J Cardiovasc Pharmacol. 2010;56:91–7.

    Article  PubMed  CAS  Google Scholar 

  28. Siller-Matula JM, Spiel AO, Lang IM, Kreiner G, Christ G, Jilma B. Effects of pantopraole and esomeprazole on platelet inhibition by clopidogrel. Am Heart J. 2009;157:e1–5.

    Article  PubMed  Google Scholar 

  29. Bhatt DL, Cryer BL, Contant CF, et al. (COGENT Investigators). Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med. 2010;363:1909–17.

    Article  PubMed  CAS  Google Scholar 

  30. Lau WC, Gurbel PA, Watkins PB, et al. The contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation. 2004;109:166–71.

    Article  PubMed  CAS  Google Scholar 

  31. Hulot JS, Bura A, Villard E, et al. Cytochrome P450 2C19 loss-offunction polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood. 2006;108:2244–7.

    Article  PubMed  CAS  Google Scholar 

  32. Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009;360:354–62.

    Article  PubMed  CAS  Google Scholar 

  33. Shuldiner AR, O’Connell JR, Bliden KP, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA. 2009;302:849–57.

    Article  PubMed  CAS  Google Scholar 

  34. Nguyen T, Frishman WH, Nawarskas J, et al. Variability of response to clopidogrel: possible mechanisms and clinical implications. Cardiol Rev. 2006;14:136–42.

    Article  PubMed  Google Scholar 

  35. • Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2009;360:363–375. Variable response to clopidogrel plays an important role in determining the appropriate regimen for different individuals. Identification of genetic factors in clopidogrel metabolism may play a role in tailoring antiplatelet therapy to individual patients.

    Article  PubMed  CAS  Google Scholar 

  36. ACCF/ACG/AHA 2010 Expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAIDS use. JACC. 2010;56:2052–2064.

    Google Scholar 

  37. Gurbel PA, Becker RC, Mann KG, Steinhubl SR, Michelson AD. Platelet function monitoring in patients with coronary artery disease. J Am Coll Cardiol. 2007;50:1822–34.

    Article  PubMed  CAS  Google Scholar 

  38. Bonello L, Tantry US, Marcucci R, et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. JACC. 2010;56:919–33.

    PubMed  CAS  Google Scholar 

  39. •• Price MJ, Berger PB, Teirstein PS, et al. (GRAVITAS Investigators). Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 2011;305:1097–1105. Despite the promise of tailoring clopidogrel therapy based on platelet inhibition, a large randomized trial failed to support this approach. Further studies will be necessary to identify better antiplatelet therapy for patients with high platelet reactivity.

    Article  PubMed  CAS  Google Scholar 

  40. Wiviott SD, Trenk D, Frelinger AL, et al. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in comparison to clopidogrel for inhibition of platelet activation and aggregation-thrombolysis in myocardial infarction 44 trial. Circulation. 2007;116:2923–32.

    Article  PubMed  CAS  Google Scholar 

  41. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001–15.

    Article  PubMed  CAS  Google Scholar 

  42. The PRISM Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM). N Engl J Med. 1998;338:1498–505.

    Article  Google Scholar 

  43. The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. Platelet Glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy. N Engl J Med. 1998;339:436–43.

    Article  Google Scholar 

  44. The EPIC Investigation. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high risk coronary angioplasty. N Engl J Med. 1994;330:956–61.

    Article  Google Scholar 

  45. Kastrati A, Mehilli J, Neumann FJ, et al. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment. JAMA. 2006;295:1531–8.

    Article  PubMed  CAS  Google Scholar 

  46. Storey RF, Husted S, Harrington RA, et al. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J Am Coll Cardiol. 2007;50:1852–6.

    Article  PubMed  CAS  Google Scholar 

  47. Husted S, Emanuelsson H, Heptinstall S, Sandset PM, Wickens M, Peters G. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J. 2006;27:1038–47.

    Article  PubMed  CAS  Google Scholar 

  48. • Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes. N Engl J Med. 2009;361:1045–1057. Ticagrelor provides an alternative to clopidogrel with improved efficacy, without an increase in major bleeding events but with a higher rate of non–CABG-related bleeding.

    Article  PubMed  CAS  Google Scholar 

  49. Bhatt DL, Lincoff AM, Gibson CM, et al. Intravenous platelet blockade with cangrelor during PCI. N Engl J Med. 2009;361:2330–41.

    Article  PubMed  CAS  Google Scholar 

  50. Harrington RA, Stone GW, McNulty S, et al. Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med. 2009;361:2318–29.

    Article  PubMed  CAS  Google Scholar 

  51. Berger JS, Roe MT, Gibson CM, et al. Safety and feasibility of adjunctive antiplatelet therapy with intravenous elinogrel, a direct-acting and reversible P2Y12 ADP-receptor antagonist, before primary percutaneous intervention in patients with ST-elevation myocardial infarction: the early rapid Reversal of platelet thrombosis with intravenous elinogrel before PCI to optimize reperfusion in acute myocardial infarction (ERASE MI) pilot trial. Am Heart J. 2009;158:998–1004.

    Article  PubMed  CAS  Google Scholar 

  52. Rao S for the INNOVATE PCI investigators. A randomized, double-blind, active controlled trial to evaluate intravenous and oral PRT060128 (elinogrel), a selective and reversible P2Y12 receptor inhibitor vs clopidogrel as a novel antiplatelet therapy in patients undergoing nonurgent percutaneous coronary interventions. Stockholm: European Society of Cardiology 2010 Congress; 2010.

  53. Becker RC, Moliterno DJ, Jennings LK, et al. Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study. Lancet. 2009;373:919–28.

    Article  PubMed  CAS  Google Scholar 

  54. Morrow DA, Scirica BM, Fox KA, et al. (TRA 2(o)P-TIMI 50 Investigators). Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 degrees P)-TIMI 50 trial. Am Heart J. 2009;158:335–41.

    Article  PubMed  CAS  Google Scholar 

  55. O’Donoghue ML, Bhatt DL, Wiviott SD, et al. (LANCELOT-ACS Investigators). Safety and tolerability of atopaxar in the treatment of patients with acute coronary syndromes: the lessons from antagonizing the cellular effects of thrombin-acute coronary syndromes trial. Circulation. 2011;123:1843–53.

    Article  PubMed  Google Scholar 

  56. Wiviott SD, Flather MD, O’Donoghue ML, et al. (LANCELOT–CAD Investigators) randomized trial of atopaxar in the treatment of patients with coronary artery disease: the lessons from antagonizing the cellular effect of thrombin-coronary artery disease trial. Circulation. 2011;123:1854–63.

    Article  PubMed  CAS  Google Scholar 

  57. Lee SW, Park SW, Hong MK, et al. Triple versus dual antiplatelet therapy after coronary stenting: impact on stent thrombosis. J Am Coll Cardiol. 2005;46:1833–7.

    Article  PubMed  CAS  Google Scholar 

  58. Tamhane U, Meier P, Chetcuti S, et al. Efficacy of cilostazol in reducing restenosis in patients undergoing contemporary stent based PCI: a meta-analysis of randomised controlled trials. EuroIntervention. 2009;5:384–93.

    Article  PubMed  Google Scholar 

  59. Suh JW, Lee SP, Park KW, et al. Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON ischemic complication after drug-eluting stenT implantation) trial. J Am Coll Cardiol. 2011;57:280–9.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Greenberg Division of Cardiology, New York Presbyterian Hospital, Weill Cornell Medical College, 520 East 70th Street, Starr-434 Pavilion, New York, NY, 10021, USA

    Luke Kim, Konstantinos Charitakis, Rajesh V. Swaminathan & Dmitriy N. Feldman

Authors
  1. Luke Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Konstantinos Charitakis
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Rajesh V. Swaminathan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Dmitriy N. Feldman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dmitriy N. Feldman.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kim, L., Charitakis, K., Swaminathan, R.V. et al. Novel Antiplatelet Therapies. Curr Atheroscler Rep 14, 78–84 (2012). https://doi.org/10.1007/s11883-011-0216-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11883-011-0216-x

Keywords

Search

Navigation